Positive News SentimentPositive NewsNYSE:ZYME Zymeworks (ZYME) Stock Forecast, Price & News $6.14 -0.05 (-0.81%) (As of 09:45 AM ET) Add Compare Share Share Today's Range$6.12▼$6.2150-Day Range$6.19▼$7.9752-Week Range$4.86▼$10.80Volume11,890 shsAverage Volume605,910 shsMarket Capitalization$416.48 millionP/E Ratio2.19Dividend YieldN/APrice Target$12.44 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Zymeworks MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside101.0% Upside$12.44 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.25) to ($1.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.46 out of 5 starsMedical Sector204th out of 975 stocksPharmaceutical Preparations Industry71st out of 455 stocks 3.3 Analyst's Opinion Consensus RatingZymeworks has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.44, Zymeworks has a forecasted upside of 101.0% from its current price of $6.19.Amount of Analyst CoverageZymeworks has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ZYME. Previous Next 0.0 Dividend Strength Dividend YieldZymeworks does not currently pay a dividend.Dividend GrowthZymeworks does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYME. Previous Next 3.3 News and Social Media Coverage News SentimentZymeworks has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Zymeworks this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for ZYME on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.MarketBeat Follows2 people have added Zymeworks to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zymeworks insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.63% of the stock of Zymeworks is held by insiders.Percentage Held by Institutions93.63% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Zymeworks are expected to grow in the coming year, from ($2.25) to ($1.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zymeworks is 2.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Zymeworks is 2.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 94.66.Price to Book Value per Share RatioZymeworks has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Zymeworks (NYSE:ZYME) StockZymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include Zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, colorectal, and endometrial cancers; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The company has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.Read More ZYME Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZYME Stock News HeadlinesSeptember 23, 2023 | americanbankingnews.comZymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from BrokeragesSeptember 22, 2023 | benzinga.comRevolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding UncertaintyOctober 3, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 11, 2023 | msn.comAdding Zymeworks To My Value Watchlist (Initial Buy Rating)August 15, 2023 | msn.comHC Wainwright & Co. Reiterates Zymeworks BC (ZYME) Neutral RecommendationAugust 15, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Hold Rating for Zymeworks (ZYME)August 11, 2023 | msn.comZymeworks GAAP EPS of -$0.76 misses by $0.27, revenue of $7M misses by $9.97MAugust 10, 2023 | seekingalpha.comZymeworks Inc. 2023 Q2 - Results - Earnings Call PresentationOctober 3, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. August 10, 2023 | markets.businessinsider.comZymeworks earnings: here's what Wall Street expectsJuly 22, 2023 | fool.comZymeworks (NYSE: ZYME)July 19, 2023 | finance.yahoo.comZymeworks To Host Second Quarter 2023 Results Conference CallJune 30, 2023 | finanznachrichten.deZymeworks Inc.: Zymeworks Appoints New DirectorJune 29, 2023 | finance.yahoo.comZymeworks Appoints New DirectorJune 28, 2023 | seekingalpha.comZymeworks joins Russell 3000, Russell 2000, and Russell microcap indexesJune 26, 2023 | finanznachrichten.deZymeworks Inc.: Zymeworks Set to Join Russell 3000, Russell 2000, and Russell Microcap IndexesJune 26, 2023 | finance.yahoo.comZymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® IndexesJune 22, 2023 | benzinga.comOver $27M Bet On Zymeworks? Check Out These 3 Stocks Insiders Are BuyingJune 20, 2023 | seekingalpha.comZymeworks: Marking TimeJune 7, 2023 | msn.comHC Wainwright & Co. Reiterates Zymeworks BC (ZYME) Prior RecommendationJune 6, 2023 | markets.businessinsider.com7 Analysts Have This to Say About ZymeworksJune 6, 2023 | markets.businessinsider.comZymeworks (ZYME) Receives a Hold from H.C. WainwrightMay 29, 2023 | markets.businessinsider.comStifel Nicolaus Remains a Buy on Zymeworks (ZYME)May 25, 2023 | markets.businessinsider.comZymeworks (ZYME) Gets a Buy from Stifel NicolausMay 18, 2023 | msn.comCitigroup Maintains Zymeworks BC (ZYME) Buy RecommendationMay 18, 2023 | marketwatch.comZymeworks President, Chief Operating Officer Neil Klompas to Leave >ZYMEMay 18, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About ZymeworksSee More Headlines Receive ZYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYME Company Calendar Last Earnings8/10/2023Today10/03/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:ZYME Previous SymbolNASDAQ:ZYME CUSIPN/A CIK1403752 Webwww.zymeworks.com Phone(302) 274-8744Fax604-737-7077Employees237Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.44 High Stock Price Forecast$19.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+101.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$2.80 Trailing P/E Ratio2.21 Forward P/E RatioN/A P/E GrowthN/ANet Income$124.34 million Net Margins41.56% Pretax Margin44.69% Return on Equity46.66% Return on Assets34.59% Debt Debt-to-Equity RatioN/A Current Ratio4.49 Quick Ratio4.49 Sales & Book Value Annual Sales$412.48 million Price / Sales1.02 Cash Flow$2.11 per share Price / Cash Flow2.93 Book Value$7.82 per share Price / Book0.79Miscellaneous Outstanding Shares67,830,000Free Float66,721,000Market Cap$419.87 million OptionableOptionable Beta0.96 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Kenneth H. Galbraith C.A. (Age 60)CEO & Chairman Comp: $1.22MDr. Christopher Astle Ph.D. (Age 43)Sr. VP & CFO Comp: $721.23kMs. Bijal Desai M.B.A.Exec. Director of Corp. Fin., FP&A & ProcurementMr. Mark Hollywood (Age 53)Exec. VP and Head of Technical & Manufacturing Operations Dr. Paul Moore Ph.D. (Age 56)Chief Scientific Officer Jack W. SpinksAssociate Director of Investor RelationsMr. Daniel Dex J.D.Ph.D., Sr. VP, Corp. Sec. & Gen. CounselDiana PapoveSr. Mang. of Corp. CommunicationsMs. Laura O'ConnorExec. Director & Head of Global HRDr. Jeffrey Smith M.D.Sr. VP of Early-Stage Devel.More ExecutivesKey CompetitorsCibusNASDAQ:CBUSAura BiosciencesNASDAQ:AURAKalVista PharmaceuticalsNASDAQ:KALVOcular TherapeutixNASDAQ:OCULDBV TechnologiesNASDAQ:DBVTView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCSold 962,266 shares on 8/24/2023Ownership: 3.562%Virginia Retirement Systems ET ALBought 177,600 shares on 8/22/2023Ownership: 0.262%California State Teachers Retirement SystemSold 6,658 shares on 8/21/2023Ownership: 0.068%Coppell Advisory Solutions LLCBought 5,661 shares on 8/17/2023Ownership: 0.008%Nuveen Asset Management LLCBought 241,800 shares on 8/16/2023Ownership: 0.356%View All Insider TransactionsView All Institutional Transactions ZYME Stock - Frequently Asked Questions Should I buy or sell Zymeworks stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ZYME shares. View ZYME analyst ratings or view top-rated stocks. What is Zymeworks' stock price forecast for 2023? 8 brokerages have issued 1-year price objectives for Zymeworks' stock. Their ZYME share price forecasts range from $8.00 to $19.00. On average, they expect the company's stock price to reach $12.44 in the next year. This suggests a possible upside of 101.0% from the stock's current price. View analysts price targets for ZYME or view top-rated stocks among Wall Street analysts. How have ZYME shares performed in 2023? Zymeworks' stock was trading at $7.86 at the beginning of 2023. Since then, ZYME stock has decreased by 21.2% and is now trading at $6.19. View the best growth stocks for 2023 here. When is Zymeworks' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our ZYME earnings forecast. How were Zymeworks' earnings last quarter? Zymeworks Inc. (NYSE:ZYME) announced its quarterly earnings data on Thursday, August, 10th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.25. The company earned $7 million during the quarter, compared to analysts' expectations of $12.86 million. Zymeworks had a net margin of 41.56% and a trailing twelve-month return on equity of 46.66%. What ETF holds Zymeworks' stock ? Invesco Russell 2000 Dynamic Multifactor ETF holds 148,747 shares of ZYME stock, representing 0.32% of its portfolio. What is Ali Tehrani's approval rating as Zymeworks' CEO? 9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend. What other stocks do shareholders of Zymeworks own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA). When did Zymeworks IPO? (ZYME) raised $65 million in an initial public offering on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager. What is Zymeworks' stock symbol? Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME." How do I buy shares of Zymeworks? Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Zymeworks' stock price today? One share of ZYME stock can currently be purchased for approximately $6.19. How much money does Zymeworks make? Zymeworks (NYSE:ZYME) has a market capitalization of $419.87 million and generates $412.48 million in revenue each year. The company earns $124.34 million in net income (profit) each year or $2.80 on an earnings per share basis. How many employees does Zymeworks have? The company employs 237 workers across the globe. How can I contact Zymeworks? Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The official website for the company is www.zymeworks.com. The company can be reached via phone at (302) 274-8744, via email at ir@zymeworks.com, or via fax at 604-737-7077. This page (NYSE:ZYME) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.